Vonoprazan-amoxicillin dual therapy for <i>Helicobacter pylori</i> eradication in Chinese population: A prospective, multicenter, randomized, two-stage study
Xueping Huang, Yi-Juan Liu, Shaowei Lin, Yan-Feng Shao, Feng Qiu, Qing-Wu Qiu, Zhang-Kun Xu, Jinxian Chen, L. Q. Chen, Zhen-Qun Lin, Wenhua Dai, Mingqing Zhang, Qi Jiang, Zhong-Qin Xiao, Xian-Xing Cheng, Xiangfei Zhang, Wen-Bin You, Wei Chen, L. Li, Weixing Lin, Yong-Fu Wang, Fu-Jin Lai, Long-Qun Chen, Zhonghua Huang, Wen‐Qi Zheng, Jinqi Wei, Zhi-Hui Lin
Abstract
BACKGROUND The efficacy of Vonoprazan-amoxicillin dual therapy (VAT) in the treatment of Helicobacter pylori (H. pylori ) is controversial. AIM To evaluate the efficacy of VAT in the Chinese population. METHODS This prospective, multicenter, randomized, open-label, and two-stage study was conducted at 23 centers in Fujian, China (May 2021-April 2022). H. pylori -infected patients were randomized to bismuth quadruple therapy (BQT), BQT-Vonoprazan (BQT-V), seven-day VAT (VAT-7), ten-day VAT (VAT-10), and fourteen-day VAT (VAT-14) groups. The primary endpoint was the H. pylori eradication rate. The secondary endpoint was the frequency of adverse events. This study was registered with the Chinese Clinical Trial Registry, ChiCTR2100045778. RESULTS In the first stage, VAT-7 and BQT-V groups were selected for early termination because less than 23 among 28 cases were eradicated. In the second stage, the eradication rates for BQT, VAT-10, and VA-14 were 80.2% [95% confidence interval (95%CI): 71.4%-86.8%], 93.2% (86.6%-96.7%), 92.2% (85.3%-96.0%) in the intention-to-treat (ITT) analysis, and 80.9% (95%CI: 71.7%-87.5%), 94.0% (87.5%-97.2%), and 93.9% (87.4%-97.2%) in the per-protocol analysis. The ITT analysis showed a higher eradication rate in the VAT-10 and VAT-14 groups than in the BQT group (P = 0.022 and P = 0.046, respectively). The incidence of adverse events in the VAT-10 and VAT-14 groups was lower than in the BQT group (25.27% and 13.73% vs 37.62%, respectively; P < 0.001). CONCLUSION VAT with a duration of 10 or 14 days achieves a higher eradication rate than the BQT, with a more tolerable safety profile in H. pylori -infected patients in Fujian.